

Margaretha Gm Roemer

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11806305/publications.pdf>

Version: 2024-02-01

14
papers

2,228
citations

1307594

7
h-index

1125743

13
g-index

15
all docs

15
docs citations

15
times ranked

3430
citing authors

#	ARTICLE	IF	CITATIONS
1	PCR-Free Shallow Whole Genome Sequencing for Chromosomal Copy Number Detection from Plasma of Cancer Patients Is an Efficient Alternative to the Conventional PCR-Based Approach. <i>Journal of Molecular Diagnostics</i> , 2021, 23, 1553-1563.	2.8	7
2	In-depth cell-free DNA sequencing reveals genomic landscape of Hodgkin's lymphoma and facilitates ultrasensitive residual disease detection. <i>Med</i> , 2021, 2, 1171-1193.e11.	4.4	24
3	Nivolumab for Relapsed/Refractory Diffuse Large B-Cell Lymphoma in Patients Ineligible for or Having Failed Autologous Transplantation: A Single-Arm, Phase II Study. <i>Journal of Clinical Oncology</i> , 2019, 37, 481-489.	1.6	265
4	Major Histocompatibility Complex Class II and Programmed Death Ligand 1 Expression Predict Outcome After Programmed Death 1 Blockade in Classic Hodgkin Lymphoma. <i>Journal of Clinical Oncology</i> , 2018, 36, 942-950.	1.6	273
5	Integrated Genetic and Topological Analysis Reveals a Hodgkin-like Mechanism of Immune Escape in T-Cell/Histiocyte-Rich Large B-Cell Lymphoma. <i>Blood</i> , 2018, 132, 1579-1579.	1.4	2
6	PD-L1 and PD-L2 Genetic Alterations Define Classical Hodgkin Lymphoma and Predict Outcome. <i>Journal of Clinical Oncology</i> , 2016, 34, 2690-2697.	1.6	634
7	Classical Hodgkin Lymphoma with Reduced β 2M/MHC Class I Expression Is Associated with Inferior Outcome Independent of β 24.1 Status. <i>Cancer Immunology Research</i> , 2016, 4, 910-916.	3.4	146
8	PD-L1 and PD-L2 Genetic Alterations Define Classical Hodgkin Lymphoma and Predict Outcome. <i>Blood</i> , 2015, 126, 176-176.	1.4	4
9	Comprehensive Analyses of Genetic Features Identify Coordinate Signatures in Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2015, 126, 3922-3922.	1.4	0
10	Diffuse Large B-Cell Lymphoma Patient-Derived Xenograft Models Capture Molecular and Biologic Heterogeneity and Inform Therapy. <i>Blood</i> , 2015, 126, 817-817.	1.4	5
11	Expression of Programmed Cell Death 1 Ligand 2 (PD-L2) Is a Distinguishing Feature of Primary Mediastinal (Thymic) Large B-cell Lymphoma and Associated With PDCD1LG2 Copy Gain. <i>American Journal of Surgical Pathology</i> , 2014, 38, 1715-1723.	3.7	138
12	Actionable Genetic Features of Primary Testicular and Primary Central Nervous System Lymphomas. <i>Blood</i> , 2014, 124, 74-74.	1.4	2
13	PD-L1 Expression Is Characteristic of a Subset of Aggressive B-cell Lymphomas and Virus-Associated Malignancies. <i>Clinical Cancer Research</i> , 2013, 19, 3462-3473.	7.0	721
14	Disruption Of Super Enhancer-Driven Cancer Dependencies In Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2013, 122, 3021-3021.	1.4	1